EFFECTIVENESS PFIZER-BIONTECH

MRNA VACCINATION AGAINST

MULTISYSTEM INFLAMMATORY
SYNDROME IN CHILDREN AMONG
PERSONS AGED 12–18 YEARS — UNITED
STATES, JULY–DECEMBER 2021
laura D. Zambrano, PhD1,*; Margaret M. Newhams, MPH2,*; Samantha M. Olson, MPH1; Natasha B. Halasa, MD3;
Ashley M. Price, MPH1; Julie A. Boom, MD4; Leila C. Sahni, PhD4; Satoshi Kamidani, MD5; Keiko M. Tarquinio,
MD6; Aline B. Maddux, MD7; Sabrina M. Heidemann, MD8; Samina S. Bhumbra, MD9; Katherine E. Bline, MD10;
Ryan A. Nofziger, MD11; Charlotte V. Hobbs, MD12; Tamara T. Bradford, MD13; Natalie Z. Cvijanovich, MD14;
Katherine Irby, MD15; Elizabeth H. Mack, MD16; Melissa L. Cullimore, MD17; Pia S. Pannaraj, MD18; Michele Kong,
MD19; Tracie C. Walker, MD20; Shira J. Gertz, MD21; Kelly N. Michelson, MD22; Melissa A. Cameron, MD23;
Kathleen Chiotos, MD24; Mia Maamari, MD25; Jennifer E. Schuster, MD26; Amber O. Orzel, MPH2; Manish M. Patel,
MD1; Angela P. Campbell, MD1,†; Adrienne G. Randolph, MD2,27,†; Overcoming COVID-19 Investigator
INTRODUCTION
 Multisystem inflammatory syndrome in children (MIS-
C) is a rare complication of SARS-CoV-2 infection that
can result in serious illness in the paediatric population.
 In the United States, Food and Drug Administration
(FDA) granted Emergency Use Authorization (EUA) for
(Pfizer-) Vaccination in children 5 through 15 years of
age. Permitted use in aged more than16 years of age.
 In recent research show that vaccination can protect
adolescent from MIS-C. However, effectiveness of two
dose Pfizer regimen to prevent MIS-C has not been
evaluated.
AIM TO THE STUDY
The purpose of this study is to evaluated effectivenss of 2
dose Pfizer regimen to against MIS-C In children
PATIENTS AND METHODS
 Assement in this journal using a test negative case control
design
 hospitalized patients aged 12-18 year at 24 pediatric
hospital in 20 states. start in first July until 9 december
2021.
This journal classified patients into two groups.
 Case-patients are define by CDC criteria for MIS-C

 hospitalized control groups included

1. patients with one or more symptoms consistent with

COVID-19, but negative result from SarCOVD PCR or
antigen test
2. patients without COVID symptoms
RESULT
RESULT
RESULT
RESULT
DISCUSSION
 In this study found that receipt of 2 doses of the
PfizerBioNTech vaccine was associated with a high level
of protection against MIS-C among patients aged 12–18
years who received their second vaccine dose ≥28 days
before hospitalization.
 This study was not designed to evaluate waning
immunity or duration of protection against MIS-C.
 This analysis is support evidence that vaccination of
children and adolescents is highly protective against
MIS-C and COVID-19
CONCLUSION
 based on the findings from the study,2 dose of Pfizer
regimen is effective to preventing MIS-C in children
JOURNAL APPRAISAL
CLINICAL QUESTION

Did the Pfizer-BioNTech mRNA Vaccination safety and efficacy to against

Multisystem Inflammatory Syndrome in Children Among Persons Aged 12–
18 Years ?
PICO
Patients Intervension Comparison Outcome
102 children aged Vacination status 181 children Clinical and
12-18 years with (2nd dose pfizer without MIS-C Severity of MIS-
MIS-C regimen) C
VALIDITY
Recruitment
Were the subjects representative? Yes!

Characteristic P value
Age grup 0,06
sex 0,01
ethnic 0,39
Month of admisson 0,35
region 0,98
VALIDITY
 Allocation

Was the assigment of subject to intervesion randomized?

NO
VALIDITY
 Allocation

Were the study group compartable? Yes

VALIDITY
 Maintance
Was the comparable study group maintained equal
intervention? Yes
VALIDITY
Measurment
Were the subjects and assesors keep blind? NO
VALIDITY
 Were the measurement objective? No
IMPORTANCY
 Is statistical significant and clinical significance reflect
to the study? Yes
APPLICABILITY
 Result reported in
the journal is
APPLICABLE
IMPORTANCY
of the research is
reflected in the
journal

Research reported in the

journal is VALID